The Cost-Effectiveness of GaitSmart Rehabilitation Programme

By Staff Writer

April 4, 2024

Understanding GaitSmart Rehabilitation Programme

GaitSmart, a rehabilitation exercise initiative, is designed to address mobility and gait issues. This CE marked class 1 medical device uses sensor-based digital technology. It monitors limb movement and assesses gait, creating a colour-coded report for patients and healthcare professionals. The test takes about 10 minutes and is usable in various settings. This fully automated, innovative technology seeks to improve gait assessment. It also aims to increase access to objective gait analysis, which could improve patient outcomes. In this article we highlight some aspects provided by The National Institute for Health and Care Excellence (NICE) in their recent review of the GaitSmart Rehabilitation Programme and its cost-effectiveness.

Clinical Effectiveness of GaitSmart

The clinical effectiveness of GaitSmart is a crucial factor in its overall value proposition. The technology has shown promising results in improving gait assessment and the choice of intervention, which could lead to improved patient outcomes. The clinical experts have noted that the risk of falls calculated by the external assessment group (EAG) was more realistic than that included in the company’s models. However, the experts have also pointed out the need for more evidence on GaitSmart’s clinical effectiveness, particularly in people at risk of falls. Ongoing and planned pilots evaluating GaitSmart’s use in the National Health Service (NHS) are expected to provide this much-needed evidence.

Cost Analysis of GaitSmart

The GaitSmart program costs about £82.00 per user. This price includes four assessment sessions and the vGym rehabilitation exercise program. It also covers the cost of hiring a healthcare assistant. The cost-saving potential of GaitSmart is significant when compared to standard care, primarily due to the reduced need for healthcare professional time and resources.

Cost Modelling and Savings

The company’s cost model revealed a cost saving of £2.90 per person using GaitSmart for fall risk, and £450.56 per person for hip and knee rehabilitation. The EAG revised these figures. They showed that GaitSmart saves £80.39 compared to standard care for hip or knee replacements. They also showed a saving of £28.70 for people at risk of falls compared to individual physiotherapy. 

Further Evidence and Research

While the current evidence strongly suggests the cost-effectiveness of GaitSmart, further research is needed to solidify these findings. Several ongoing pilots evaluating GaitSmart’s use in the NHS could address existing uncertainties and provide more robust evidence of its benefits.

Reference url

Recent Posts

UK Medicine Payment Rates
      

Revitalizing Innovation: The Impact of UK Medicine Payment Rates

💡 Are the UK’s medicine payment rates stifling innovation in life sciences?

Recent analysis reveals that the staggering 23.5% payment rate for pharmaceuticals is not just limiting NHS spending but also curtailing R&D investments, delaying new drug launches, and threatening workforce stability. If we can lower these rates to below 10%, we could unleash significant growth and restore the UK’s competitive edge in the global life sciences landscape.

Discover the critical insights and recommendations that could reshape the future of healthcare in the UK.

#SyenzaNews #healthcarepolicy #innovation

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

Enhertu reimbursement analysis
                 

Enhertu Reimbursement Analysis: Navigating Cost-Effectiveness Challenges

💡 How do we balance groundbreaking cancer treatments with budget realities?

The recent analysis by the Dutch Healthcare Institute on Enhertu shines a light on the complexities of integrating innovative therapies for HER2-low metastatic breast cancer into national insurance packages. While the clinical efficacy is evident, the substantial cost implications and demand for steep price reductions bring significant challenges to market access.

Explore the nuances of this vital discussion on clinical effectiveness, economic evaluation, and the future of pricing strategies in oncology.

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.